Ebola virus and Marburg virus are single-stranded, enveloped and negative sense-RNA viruses belonging to the Filoviridae family, and they both cause deadly hemorrhagic fevers in humans and mammals.
Over-colonization and subsequent inflammation triggered by Cutibacterium acnes is the primary factor in the pathogenesis of acne vulgaris, a prevalent skin condition among adolescents. Gyeongsang National University has discovered and characterized new antimicrobial peptides (AMPs) as candidates for the treatment of acne vulgaris.
Around one-third of patients with acute myeloid leukemia (AML) harbor FLT3 gene mutations which are associated with poor prognosis and high risk of relapse. Several compounds targeting FLT3 internal tandem duplication (ITD) have been developed in the past decades, but none has overcome myelosuppressive toxicity caused by the simultaneous inhibition of FLT3 and c-Kit. Therefore, there is a need for new treatment options.
Pancreatic cancer is a challenge due to its poor prognosis and high mortality rate, highlighting the need for new therapeutic approaches. Previous findings have shown that AUS-001 inhibits β-tubulin polymerization through its unique binding to the tubulin’s colchicine site.
Lifearc has announced a collaboration with Neuropeutics Inc. to develop a new small molecule for the treatment of motor neuron disease (MND), or amyotrophic lateral sclerosis (ALS). Neuropeutics and Lifearc intend to develop a lead candidate therapeutic to prevent and reverse TDP-43 protein aggregation in MND/ALS.
At the recent ASCO Gastrointestinal Cancers symposium, Cyclacel Ltd. presented preclinical data for the Polo-like kinase 1 (PLK1) inhibitor plogosertib from assessment in models of colorectal cancer.
Helicore Biopharma Inc. has emerged from stealth with $65 million in series A financing and a focus on first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists for obesity and related conditions. The company’s portfolio includes GIP antibody conjugates designed to address specific obesity subpopulations.
Theranib Inc. has divulged retinal dehydrogenase 1 (ALDH1A1; RALDH1) and/or retinal dehydrogenase 2 (ALDH1A2; RALDH2) and/or aldehyde dehydrogenase family 1 member A3 (ALDH1A3; RALDH3) inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.
RSS
